



Journal home page: <http://www.journalijar.com>

INTERNATIONAL JOURNAL
OF INNOVATIVE AND APPLIED RESEARCH

REVIEW ARTICLE

Article DOI:10.58538/IJAR/2069

DOI URL: <http://dx.doi.org/10.58538/IJAR/2069>

Hematocrit Variations in HIV Patients Co-infected with Malaria: A Comprehensive Review

*Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu², Hauwa Ali Buhari³ and Asiya Imam Umar⁴

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²School of Nursing Science, Kampala International University, Uganda.

³Department of Haematology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.

⁴Department of Medical Microbiology, School of Medical Laboratory Sciences, Usmanu Danfodiyo University, Sokoto, Nigeria.

Manuscript Info

Manuscript History

Received: 25 November 2023

Final Accepted: 10 January 2024

Published: January 2024

Keywords:

Hematocrit, HIV, malaria, co-infection, variations, anemia, pathophysiology, diagnosis, treatment, complications

Abstract

Co-infection with both HIV and malaria presents a complex medical challenge, particularly concerning hematocrit variations that often result in anemia in affected individuals. This comprehensive review aims to explore and synthesize existing literature to elucidate the multifaceted nature of hematocrit alterations observed in HIV patients concurrently infected with malaria. The pathophysiological mechanisms contributing to hematocrit variations in this co-infected population involve a complex interplay between the immunosuppressive effects of HIV and the hemolytic nature of malaria parasites. Understanding these mechanisms is crucial for developing targeted interventions. Diagnostic challenges abound due to overlapping symptoms and limitations in conventional diagnostic tools, necessitating the exploration of more advanced diagnostic methodologies to accurately assess and monitor hematocrit levels in co-infected individuals. The clinical implications of hematocrit variations in this context extend beyond mere anemia, impacting disease severity, treatment response, and the overall prognosis of affected patients. Anemia complicates therapeutic

interventions, potentially affecting the efficacy of antiretroviral and antimalarial treatments. Persistent anemia in co-infected individuals increases vulnerability to opportunistic infections and compromises treatment outcomes, underscoring the necessity for comprehensive management strategies. These strategies encompass a holistic approach involving antiretroviral therapies, antimalarial drugs, nutritional support, and potential interventions such as blood transfusions in severe cases. In conclusion, this review consolidates current knowledge, emphasizing the need for further research to elucidate the nuances of hematocrit variations in HIV patients co-infected with malaria. Improved understanding, enhanced diagnostic modalities, and optimized management strategies are crucial to mitigate the impact of anemia and improve outcomes in this vulnerable patient population.

.....
**Corresponding Author:- Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.*
.....

Introduction

The coexistence of HIV and malaria presents a significant public health challenge in regions where both diseases are endemic. Among the myriad complications arising from this co-infection, hematocrit variations, notably anemia, stand as a prevalent and consequential manifestation. Anemia, characterized by alterations in hematocrit levels, is a key hematological feature observed in individuals affected by both HIV and malaria, amplifying the complexity of their clinical management [1-10]. Understanding the nuances of hematocrit variations in this specific context is paramount, considering the distinctive pathophysiological mechanisms at play when HIV and malaria co-occur. HIV infection engenders a state of immunosuppression, leaving individuals more susceptible to severe malarial infections, which, in turn, intensify hemolysis and exacerbate anemia. Concurrently, malaria parasites directly affect red blood cells, causing hemolysis and shortening their lifespan, thereby contributing to further declines in hematocrit levels among HIV-positive individuals [11-26].

This paper aims to delve into the intricate interplay of factors driving hematocrit alterations in HIV patients co-infected with malaria. By examining the pathophysiology underpinning these variations, elucidating the diagnostic challenges, and delineating the implications for disease management, this review seeks to provide a comprehensive understanding of this complex medical scenario. Hematocrit serves not only as a biomarker of anemia but also as an indicator of disease severity and treatment response in this vulnerable population. Diagnostic challenges arising from the overlapping manifestations of both diseases necessitate a closer examination of advanced diagnostic techniques that might offer more accurate assessments of hematocrit levels in co-infected individuals. Moreover, the clinical implications extend beyond the hematological domain, impacting the overall prognosis and therapeutic interventions. The complications

associated with persistent anemia in co-infected individuals encompass increased susceptibility to opportunistic infections and compromised treatment outcomes, warranting multidisciplinary approaches to management. In essence, this paper endeavors to consolidate existing knowledge, identify research gaps, and highlight the critical need for tailored approaches to diagnosis and management to address hematocrit variations in HIV patients co-infected with malaria. Improved understanding and targeted interventions hold the promise of ameliorating the burden of anemia and enhancing the well-being of individuals grappling with this intricate dual infection.

Pathophysiological Mechanisms

The pathophysiological mechanisms underlying hematocrit variations in HIV patients co-infected with malaria are multifaceted, involving intricate interactions between the immune system, red blood cells (RBCs), and the respective disease pathogens [27-37]. HIV infection induces progressive immunosuppression by primarily targeting CD4+ T lymphocytes, compromising the immune response against various pathogens, including malaria. This weakened immune system exacerbates the severity of malarial infections, leading to increased parasitemia and higher rates of hemolysis [38-52].

Malarial parasites, particularly *Plasmodium falciparum*, invade RBCs, leading to their destruction (hemolysis) as part of the parasite's life cycle. The presence of HIV exacerbates this process, causing heightened hemolysis and a subsequent decline in RBC count and hematocrit levels. The destruction of RBCs compromises the oxygen-carrying capacity, contributing to anemia in co-infected individuals [53-71].

Malarial infection not only leads to increased destruction of RBCs but also reduces their lifespan. This reduced lifespan, combined with the effects of HIV on erythropoiesis and bone marrow function, further diminishes RBC production, aggravating the decline in hematocrit levels [72-77].

Both HIV and malaria infections trigger inflammatory responses and dysregulate cytokine production. Chronic inflammation associated with HIV infection and the immune response against malaria parasites can disrupt erythropoiesis, impairing the production and maturation of RBCs and contributing to anemia [78-83]. Co-infected individuals often face nutritional deficiencies due to increased metabolic demands, poor dietary intake, or malabsorption associated with both diseases. These deficiencies can further compromise erythropoiesis and exacerbate anemia in the context of HIV-malaria co-infection [84-93].

Understanding these intricate pathophysiological mechanisms is pivotal for developing targeted interventions aimed at mitigating hematocrit variations and managing anemia in individuals simultaneously grappling with HIV and malaria. It underscores the need for multifaceted approaches that address both the immune dysregulation caused by HIV and the hemolytic nature of malaria parasites to effectively manage hematocrit alterations in co-infected individuals [94-98].

Diagnostic Challenges

Accurately diagnosing and monitoring hematocrit variations in HIV patients co-infected with malaria presents substantial challenges owing to the overlapping clinical manifestations and limitations of conventional diagnostic methods. The symptoms of HIV, malaria, and anemia often overlap, making it challenging to attribute hematocrit variations solely to malaria or HIV [99]. Fatigue, fever, and malaise, common in both diseases, may mask specific hematological alterations, necessitating precise diagnostic tools for differentiation. Traditional methods, such as microscopic examination of blood smears for malaria parasites and CD4 cell counts for HIV diagnosis and monitoring, may not provide a comprehensive assessment of hematocrit variations or the severity of anemia in co-infected individuals [100]. Some malaria infections remain submicroscopic and undetectable by standard diagnostic tests, leading to underestimations of the prevalence and impact of malaria on hematocrit levels in HIV-positive individuals. In resource-limited settings, where these co-infections are prevalent, sophisticated diagnostic tools like molecular assays or flow cytometry for precise hematological assessments may not be readily available or affordable. HIV infection itself can cause hematological alterations, including anemia, independent of malaria co-infection [101]. Distinguishing between the contribution of HIV and malaria to hematocrit variations requires nuanced diagnostic approaches. Co-administration of antiretroviral and antimalarial medications can affect hematocrit levels and mask the true impact of each infection on anemia. Additionally, co-morbidities, such as tuberculosis or gastrointestinal infections, may further complicate hematological assessments. Advanced tests like polymerase chain reaction (PCR) for detecting low-level parasitemia or assessing erythropoietin levels for erythropoiesis evaluation may not be accessible in many healthcare settings where co-infections are prevalent.

Clinical Implications

The hematocrit variations observed in HIV patients co-infected with malaria carry significant clinical implications that span disease severity, treatment response, and overall patient outcomes. Understanding these implications is crucial for tailored patient management strategies [102]. Hematocrit levels serve as critical indicators of disease severity in co-infected individuals. Lower hematocrit levels often correlate with increased disease severity, highlighting the importance of monitoring hematocrit as a prognostic marker. Monitoring hematocrit variations aids in assessing treatment responses to both HIV and malaria therapies. Persistent anemia or declining hematocrit levels may signal inadequate response to treatments, requiring adjustments in therapeutic regimens.

Anemia resulting from hematocrit variations can exacerbate morbidity in co-infected patients. It increases vulnerability to opportunistic infections, impairs physical performance, and contributes to fatigue, ultimately impacting the quality of life. Hematocrit variations may affect the effectiveness or tolerability of antiretroviral therapy (ART) in HIV patients. Certain ART medications might exacerbate anemia or interact with antimalarial drugs, necessitating careful selection and monitoring. Severe anemia associated with hematocrit variations may require blood transfusions to alleviate symptoms and prevent complications. However, frequent transfusions pose challenges in resource-limited settings due to availability and potential risks. Addressing nutritional deficiencies and implementing supplementation strategies becomes imperative in managing anemia and optimizing hematocrit levels. Adequate nutrition supports erythropoiesis and helps mitigate anemia-associated complications. Persistent anemia resulting from hematocrit

variations in co-infection scenarios can influence long-term outcomes. Chronic anemia might contribute to increased mortality rates and poorer overall prognoses if not managed effectively.

Complications and Management

Persistent anemia compromises the immune system, heightening vulnerability to opportunistic infections. Co-infected individuals are at a heightened risk of bacterial, viral, and parasitic infections, exacerbating overall morbidity. Chronic anemia adversely affects daily functioning, leading to fatigue, weakness, and reduced physical stamina. These symptoms significantly impact the quality of life of co-infected individuals, impairing their ability to perform daily activities. Anemia can interfere with the effectiveness of antiretroviral therapy (ART) and antimalarial treatments. Diminished hematocrit levels may reduce the efficacy of medications or cause adverse reactions, potentially compromising treatment outcomes [103]. In cases of severe and chronic anemia, cognitive impairment and developmental delays, particularly in children co-infected with HIV and malaria, may manifest due to insufficient oxygen supply to the brain during crucial developmental stages. Severe anemia associated with hematocrit variations significantly elevates the risk of mortality in co-infected individuals. The cumulative impact of compromised immunity and reduced oxygen-carrying capacity heightens the risk of fatal outcomes.

Management Strategies

Tailoring ART and antimalarial regimens to minimize adverse effects on hematocrit levels while ensuring optimal disease management is crucial. Adjustments may be necessary to balance efficacy and tolerability [104]. Addressing nutritional deficiencies and providing iron, folate, and vitamin supplementation is essential to support erythropoiesis and mitigate anemia-associated complications. In cases of severe anemia, blood transfusions may be necessary to raise hematocrit levels and alleviate symptoms. However, careful consideration of transfusion thresholds and risks associated with transfusions is crucial. Regular monitoring of hematocrit levels, along with comprehensive clinical assessments, is vital to track disease progression, treatment response, and the effectiveness of management strategies. Patient education regarding the importance of treatment adherence, nutritional support, and recognizing symptoms of complications is imperative. Support programs can assist patients in coping with the challenges associated with co-infection. Continual research efforts focusing on novel therapies, diagnostic tools, and management approaches are essential to improve outcomes and alleviate the burden of hematocrit variations in co-infected individuals. Implementing multifaceted management strategies that address complications, optimize treatments, and support patient well-being is crucial in mitigating the impact of hematocrit variations in HIV patients co-infected with malaria and improving their overall prognosis.

Conclusion

Hematocrit variations in individuals co-infected with HIV and malaria represent a complex interplay of pathophysiological mechanisms that significantly impact disease management, patient outcomes, and overall well-being. The intricate interactions between these infections exacerbate hematological alterations, predominantly anemia, posing diagnostic, therapeutic, and

prognostic challenges. The pathophysiological mechanisms involving HIV-mediated immunosuppression, malaria-induced hemolysis, and inflammatory responses contribute synergistically to hematocrit variations. Despite advancements in diagnostic tools, accurately differentiating the contributions of each infection to hematocrit changes remains challenging, especially in resource-limited settings. The clinical implications of hematocrit variations extend beyond anemia, encompassing disease severity, treatment response, and long-term outcomes. Persistent anemia not only compromises immune function but also hampers treatment efficacy, potentially leading to increased morbidity and mortality.

Managing hematocrit variations and associated complications requires a multidimensional approach. Optimization of antiretroviral and antimalarial therapies, nutritional supplementation, careful monitoring, and supportive care are vital components of comprehensive management strategies. Furthermore, addressing diagnostic limitations and fostering research initiatives are essential to refine diagnostic modalities and therapeutic interventions. Efforts aimed at improving diagnostic accuracy, advancing treatment modalities, and enhancing patient support and education are imperative. By addressing these challenges, healthcare professionals and researchers can pave the way toward better management strategies, ultimately alleviating the burden of hematocrit variations in HIV patients co-infected with malaria and improving the quality of life and outcomes for these vulnerable populations. Continued collaborative efforts in research, innovation, and resource allocation are essential to meet the evolving needs of these complex co-infections.

References

1. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
2. Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-8. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
3. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
4. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.22192/ijcrms.2017.03.01.004).
5. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-9.
6. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38. DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)

7. Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci.* 2023;9(2): 1-5. DOI: [10.22192/ijcrms.2023.09.02.001](https://doi.org/10.22192/ijcrms.2023.09.02.001)
8. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-9.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-9.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Bassey JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International.* 2020;32(22):101-9.
12. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation.* 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).
13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences.* 2015;4(4):911-
[6.https://www.academia.edu/download/38320140/Obeagu Emmanuel Ifeanyi and Obeagu Getrude Uzoma2.EMMA1.pdf](https://www.academia.edu/download/38320140/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf).
14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci.* 2016;3(10): 55-65. DOI; [10.22192/ijarbs.2016.03.10.009](https://doi.org/10.22192/ijarbs.2016.03.10.009)
15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-5. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001)
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):110-9.
17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanjo CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State, Nigeria. *J. Bio. Innov.* 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://doi.org/10.22192/ijcrms.2023.09.02.001).

18. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri.* 2022; 5 (6). 2022;130.[links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://doi.org/10.22192/ijcrms.2017.03.02.005).
19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev.* 2015; 3:139-144.https://www.academia.edu/download/38320159/Obeagu_Emanuel_Ifeanyi3_et_al_IJCRAR.pdf.
20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. *Ann Clin Lab Res.* 2018;6(1):1-4.[links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://doi.org/10.22192/ijcrms.2017.03.02.005)
21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. *Int. J. Curr. Res. Med. Sci.* 2017;3(2): 28-34.DOI: [10.22192/ijcrms.2017.03.02.005](https://doi.org/10.22192/ijcrms.2017.03.02.005)
22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Science Reports.* 2023;6(8):e1450.
23. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. *J Pub Health Nutri.* 2023; 6 (1). 2023;139.[links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://doi.org/10.22192/ijcrms.2017.03.02.005).
24. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. *Madonna University journal of Medicine and Health Sciences.* 2022;2(3):128-34.<https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
25. Walter O, Anaeho QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. *Journal of Pharmaceutical Research International.* 2022;29-34.
26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Basse JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. *Journal of Pharmaceutical Research International.* 2020;32(24):9-18.
27. Obeagu EI, Obeagu GU, Chukwueze CM, Ikpenwa JN, Ramos GF. EVALUATION OF PROTEIN C, PROTEIN S AND FIBRINOGEN OF PREGNANT WOMEN WITH MALARIA IN OWERRI METROPOLIS. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022;2(2):1-9.
28. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfectd with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2017;3(5):100-4.

29. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine*. 2023;102(46): e36166.
30. Obeagu EI, Chijioke UO, Ekelozie IS. Malaria rapid diagnostic test (RDTs). *Ann Clin Lab Res*. 2018;6(4):275.
31. Obeagu EI, Alum EU, Ugwu OP. Hepcidin: The Gatekeeper of Iron in Malaria Resistance. 2023.
32. Ogomaka IA, Obeagu EI. Methods of Breast Feeding as Determinants of Malaria Infections among Babies in IMO State, Nigeria. *International Journal of Medical Science and Dental Research*. 2019;2(01):17-24.
33. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. *J Pub Health Nutri*. 2022; 5 (8). 2022;137.[links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015).
34. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):135-42.DOI: [10.22192/ijarbs.2023.10.09.015](https://doi.org/10.22192/ijarbs.2023.10.09.015) [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
35. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. *Int. J. Adv. Res. Biol. Sci*. 2023;10(9):128-34.DOI: [10.22192/ijarbs.2023.10.09.014](https://doi.org/10.22192/ijarbs.2023.10.09.014) [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
36. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci*. 2017;3(5):100-4.DOI: [10.22192/ijcrms.2017.03.05.014](https://doi.org/10.22192/ijcrms.2017.03.05.014) https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
37. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. *South Asian Journal of Research in Microbiology*. 2022;13(2):26-31.
38. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian Journal of Dental and Health Sciences*. 2023;3(2):7-14.<http://ajdhs.com/index.php/journal/article/view/39>.
39. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. *J Clin Commun Med*. 2020;2(3):180-83.DOI:DOI: [10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf](https://doi.org/10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunosorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf).

40. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. *Journal of Pharmaceutical Research International*. 2021;33(47A):78-84.
41. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. *Asian Journal of Pregnancy and Childbirth*. 2023 Jul 29;6(1):203-11. <http://research.sdpublishers.net/id/eprint/2819/>.
42. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. *Asian Journal of Research in Infectious Diseases*. 2022;10(4):1-7.
43. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. *Journal of Pharmaceutical Research International*. 2021;33(57A):360-8.
44. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):42-57. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
45. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
46. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. *European Journal of Pharmaceutical and Medical Research*, 2023;10(8): 564-568
47. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. *World Journal of Pharmacy and Pharmaceutical Sciences*, 2015; 4(3): 153-160. <links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf>.
48. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol*. 2015;2(4):45-9.
49. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretro viral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2019;6(12):45-8. DOI: [10.22192/ijcreps.2019.06.12.004](https://doi.org/10.22192/ijcreps.2019.06.12.004) <links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretro-viral-therapy-a-review-of-prevalence.pdf>.

50. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13. DOI: [10.22192/ijcrms.2023.09.02.002](https://doi.org/10.22192/ijcrms.2023.09.02.002)
[links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf](https://www.ijcrms.com/links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf).
51. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. [links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf](https://www.ijcrms.com/links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf).
52. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-10. https://www.academia.edu/download/38320134/Obeagu_Emanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
53. Obeagu EI, Obeagu GU, Egba SI, Emeka-Obi OR. Combatting Anemia in Pediatric Malaria: Effective Management Strategies. *Int. J. Curr. Res. Med. Sci.* 2023;9(11):1-7.
54. Hassan AO, Oso OV, Obeagu EI, Adeyemo AT. Malaria Vaccine: Prospects and Challenges. *Madonna University journal of Medicine and Health Sciences* ISSN: 2814-3035. 2022;2(2):22-40.
55. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(4):10-9.
56. Obeagu EI, Busari AI, Uduchi IO, Ogomaka IA, Ibekwe AM, Vincent CC, Chijioke UO, Okafor CJ, Okoroiwu HU, Adike CN. Age-Related Haematological Variations in Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(42B):218-24.
57. Ogomaka IA, Obeagu EI. Malaria in Pregnancy Amidst Possession of Insecticide Treated Bed Nets (ITNs) in Orlu LGA of Imo State, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(41B):380-6.
58. Ogbonna CO, Obeagu EI, Ufelle SA, Ogbonna LN. Evaluation of haematological alterations in children infected by *Plasmodium falciparum* Species in Enugu, Enugu State, Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(1):38-45.
59. Okorie HM, Obeagu EI, Obarezi HC, Anyiam AF. Assessment of some inflammatory cytokines in malaria infected pregnant women in Imo State Nigeria. *International Journal of Medical Science and Dental Research.* 2019;2(1):25-36.
60. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
61. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS).* 2023;3(2):28-31.
62. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. AIDS: A Review. *Newport International Journal of Public Health and Pharmacy (NIJPP).* 2023;3(2):64-7.
63. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS).* 2023;3(2):95-9.

64. Ibebuike JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1 (2):08-14. <https://www.ijmsdr.org/published%20paper/li1i2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
65. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci*. 2014; 5:825-30.
66. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharama Research*. 2014; 391:186-9.
67. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023; 3 (1): 7-12.
68. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research*. 2022;10(5):1-1.
69. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanne CA, Nwanjo HU, Amadike JN, Eemma MC, Okpomeshine EA, Ozims SJ, Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-71.
70. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sick Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
71. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci*. 2018;4(2):104-8.
72. Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-9.
73. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of some haematological parameters in malaria infected pregnant women in Imo state Nigeria. *Int. J. Curr. Res. Biol. Med*. 2018;3(9):1-4.
74. Nwosu DC, Obeagu EI, Ezenwuba C, Agu GC, Amah H, Ozims SJ, Nwanjo HU, Edward A, Izuchukwu IF, Amadike JN, Nwagwu AJ. Antioxidant status of children with Plasmodium falciparum malaria in Owerri municipal council of Imo state. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2016;3(8):40-6.
75. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci*. 2018;5(6):60-6.
76. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).

77. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Oduanze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-5.
78. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International.* 2021;33(52B):10-9.
79. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore).* 2023;102(49): e36599. doi: 10.1097/MD.00000000000036599. PMID: 38065920; PMCID: PMC10713174.
80. Anyiam AF, Arinze-Anyiam OC, Irondi EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore).* 2023;102(47): e36342. doi: 10.1097/MD.00000000000036342. PMID: 38013335; PMCID: PMC10681551.
81. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore).* 2023;102(47): e35910. doi: 10.1097/MD.00000000000035910. PMID: 38013350; PMCID: PMC10681510.
82. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore).* 2023;102(46): e36166. doi: 10.1097/MD.00000000000036166. PMID: 37986340; PMCID: PMC10659731.
83. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore).* 2023;102(41): e35673. doi: 10.1097/MD.00000000000035673. PMID: 37832059; PMCID: PMC10578718.
84. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep.* 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
85. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS).* 2023;3(3).
86. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.

87. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
88. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-9.
89. Okamgba OC, Nwosu DC, Nwobodo EI, Agu GC, Ozims SJ, Obeagu EI, Ibanga IE, Obioma-Elemba IE, Ihekaire DE, Obasi CC, Amah HC. Iron Status of Pregnant and Post-Partum Women with Malaria Parasitaemia in Aba Abia State, Nigeria. *Annals of Clinical and Laboratory Research*. 2017;5(4):206.
90. Anyiam AF, Arinze-Anyiam OC, Omosigho PO, Ibrahim M, Irondi EA, Obeagu EI, Obi E. Blood Group, Genotype, Malaria, Blood Pressure and Blood Glucose Screening Among Selected Adults of a Community in Kwara State: Implications to Public Health. *Asian Hematology Research Journal*. 2022;6(3):9-17.
91. Obeagu EI, Nimo OM, Bunu UO, Ugwu OP, Alum EU. Anaemia in children under five years: African perspectives. *Int. J. Curr. Res. Biol. Med.* 2023; 1:1-7.
92. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):6-15.
93. Offie DC, Ibekwe AM, Agu CC, Esimai BN, Okpala PU, Obeagu EI, Ufelle SA, Ogbonna LN. Fibrinogen and C-Reactive Protein Significance in Children Infected by *Plasmodium falciparum* Species in Enugu, Enugu State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(15):1-8.
94. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research*. 2023;11(10):01-6.
95. Okorie HM, Obeagu EI, Eze EN, Jeremiah ZA. Assessment of coagulation parameters in malaria infected pregnant women in Imo state, Nigeria. *International Journal of Current Research in Medical Sciences*. 2018;4(9):41-9.
96. Ogbonna LN, Ezeoru VC, Ofodile AC, Ochiabuto OM, Obi-Ezeani CN, Okpala PU, Okafor CJ, Obeagu GU, Busari AI, Obeagu EI. Gender Based Variations of Haematological Parameters of Patients with Asymptomatic Malaria in Akure, Ondo State, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(8):75-80.
97. Eberendu IF, Ozims SJ, Agu GC, Amah HC, Obasi CC, Obioma-Elemba JE, Ihekaire DE, Ibanga IE, Amah CC, Obeagu EI, Nwosu DC. Impact of human activities on the breeding of mosquitoes of human disease in Owerri metropolis, Imo state. *Int J Adv Res Biol Sci IJARBS*. 2017;4(12):98-106.
98. Obeagu EI, Ofodile AC, Okwuanaso CB. A review on socio economic and behavioral aspects of malaria and its control among children under 5 years of age in Africa. *J Pub Health Nutri*. 2023; 6 (1): 136.
99. Roberds A, Ferraro E, Luckhart S, Stewart VA. HIV-1 impact on malaria transmission: a complex and relevant global health concern. *Frontiers in Cellular and Infection Microbiology*. 2021; 11:656938.
100. Sing'oei V, Ochola J, Owuoth J, Otieno J, Rono E, Andagalu B, Otieno L, Nwoga C, Copeland NK, Lawlor J, Yates A. Clinical laboratory reference values in adults in

- Kisumu County, Western Kenya; hematology, chemistry and CD4. *Plos one*. 2021;16(3): e0249259.
101. Beyene HB, Tadesse M, Disassa H, Beyene MB. Concurrent Plasmodium infection, anemia and their correlates among newly diagnosed people living with HIV/AIDS in Northern Ethiopia. *Acta Tropica*. 2017; 169:8-13.
 102. Anyanwu NC, Oluwatimileyin DJ, Sunmonu PT. Status of anaemia and malaria co-infection with HIV From HAART clinics in federal capital territory, Nigeria: A cross-sectional study. *Microbiology Insights*. 2020; 13:1178636120947680.
 103. Beletew B, Mengesha A, Ahmed M, Fitwi A, Wudu M. Determinants of anemia among HIV-positive children on highly active antiretroviral therapy attending hospitals of North Wollo Zone, Amhara Region, Ethiopia, 2019: a Case-Control Study. *Anemia*. 2020.
- Moore BR, Davis TM. Updated pharmacokinetic considerations for the use of antimalarial drugs in pregnant women. *Expert Opinion on Drug Metabolism & Toxicology*. 2020;16(9):741-58.